Arisan Therapeutics is a clinical stage company focused on the development of convenient, small molecule oral therapeutics for neglected and emerging viral diseases. A number of these infectious diseases have the potential for significant impact on public health including pandemic potential and have been classified as priority biodefense-related pathogens.
Our scientific team is comprised of virologists, biologists, and medicinal chemists with extensive drug discovery and development experience. Our efforts are further supported by a host of highly experienced collaborators, consultants and through funding from the Defense Threat Reduction Agency (DTRA), Battelle Memorial Institute and the National Institute for Allergy and Infectious Disease (NIAID).
To identify unmet medical needs and provide appropriate solutions through development, collaboration and partnerships to benefit patients and to defend against potential life-threatening infectious diseases.